Alchemia Limited (ASX: ACL) has licenced two early stage anticancer drug candidates from Cancer Research Technology and will evaluate them in various cancer and cancer stem cell models.
The preclinical Focal Adhesion Kinase inhibitors will be evaluated on their effect on the tumour environment and cancer stem cells that are essential for the growth, persistence and reoccurrence of cancer.
FAK is a non-receptor tyrosine kinase that plays an important role in the development and spread of numerous malignancies and has therefore emerged as a promising target in cancer therapy.
Inhibition of FAK has the potential to provide numerous therapeutic benefits to cancer patients by disrupting tumour development and metastasis, while overcoming chemo-resistance to a broad variety of currently used cytotoxic drugs.
FAK inhibitors have the potential to treat a range of cancers and may provide a longer lasting clinical response and improved patient outcomes.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.